Active Ingredient History
Finerenone, sold under the brand name Kerendia and Firialta, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). It is taken orally. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Chronic Kidney Disease-Mineral and Bone Disorder (approved 2021)
Diabetes Mellitus, Type 2 (approved 2021)
Albuminuria (Phase 4)
Child (Phase 3)
Diabetes Complications (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 3)
Heart Failure (Phase 3)
Hyperaldosteronism (Phase 4)
Hypertension (Phase 4)
Kidney Transplantation (Phase 2)
Pharmacokinetics (Phase 1)
Pharmacology, Clinical (Phase 1)
Proteinuria (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue